Skip to main content
Sarepta Therapeutics, Inc. logo

Sarepta Therapeutics, Inc. — Investor Relations & Filings

Ticker · SRPT ISIN · US8036071004 LEI · 549300IKDPIED8J8IG21 US Manufacturing
Open in API
Filings indexed 1,061 across all filing types
Latest filing 2023-08-05 Regulatory Filings
Country US United States of America
Listing US SRPT

About Sarepta Therapeutics, Inc.

https://www.sarepta.com/

Sarepta Therapeutics is a commercial-stage biopharmaceutical company that engineers precision genetic medicines for rare diseases. The company's research and development efforts are centered on RNA-targeted therapeutics and gene therapies, with a primary focus on treating rare neuromuscular and central nervous system disorders. Sarepta aims to accelerate the drug development process from discovery to patient application and is building significant gene therapy manufacturing capabilities to support its mission.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2023
Regulatory Filings
2023-08-05 English
S-8
Regulatory Filings Classification · 95% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is used to register securities to be offered under employee benefit plans such as equity incentive plans and employee stock purchase plans. It includes details about the number of shares registered, references to prior filings, exhibits related to the equity plans, and signatures of company officers and directors. There is no financial performance data, earnings information, or management discussion of results. The document is a regulatory filing related to securities registration rather than a financial report or announcement of voting results. Therefore, it fits best under the category of Regulatory Filings (RNS). The document length is 7405 characters, which is consistent with a full registration statement rather than a brief announcement.
2023-08-02 English
10-Q
Interim / Quarterly Report Q2 2023
2023-08-02 English
8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated June 22, 2023. It discloses an investor webcast presentation related to a gene therapy product ELEVIDYS, including pricing information. The document explicitly states that the presentation is furnished as Exhibit 99.1 and that the information is furnished pursuant to Item 7.01 (Regulation FD Disclosure). The document is short (3812 characters) and primarily serves as a disclosure of an event and furnishing of a presentation, not a full financial report or earnings release. The presence of a presentation exhibit and the nature of the disclosure aligns with an Investor Presentation (IP) filing type rather than a full report or earnings release. Therefore, the best classification is Investor Presentation (IP).
2023-06-22 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce significant events or disclosures by a company. The text includes a Regulation FD Disclosure about FDA accelerated approval of a gene therapy product and references an attached press release. The document is short (3891 characters) and primarily serves as an announcement of an event rather than a detailed financial report or earnings release. It does not contain financial statements or detailed financial analysis. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2023-06-22 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC, dated June 8, 2023. It reports on the results of the company's Annual Meeting of stockholders, including voting outcomes on director elections, executive compensation advisory votes, amendments to equity incentive plans, and ratification of the independent auditor. The document includes detailed voting results and descriptions of proposals submitted to shareholders. This type of filing is a regulatory announcement of voting results from a shareholder meeting, which corresponds to the category 'Declaration of Voting Results & Voting Rights Announcements' (DVA). The document is not an annual report, earnings release, or proxy solicitation, but specifically reports the voting outcomes. The length and content confirm it is not merely an announcement of a report but the actual voting results report.
2023-06-09 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.